Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- ATTR-CM diagnosis is assembled from phenotype, monoclonal testing, and confirmatory imaging rather than a single positive study.
- Compatible echo or MRI findings can raise suspicion, but they aren’t specific enough to establish diagnosis alone.
- Abnormal monoclonal studies weaken the certainty of an imaging-based nonbiopsy diagnosis and raise concern for amyloid light chain (AL) amyloidosis.
- TTR genetic testing subtypes ATTR after the diagnosis is in focus; it doesn’t anchor the diagnosis by itself.
Why ATTR-CM Diagnosis Is Assembled, Not Single-Test
ATTR-CM is usually diagnosed by assembling multiple lines of evidence rather than by relying on a single test result. A compatible cardiac phenotype raises suspicion, but the diagnosis becomes more secure only by interpreting monoclonal protein assessment and bone-avid tracer imaging within the same workup. This structured interpretation helps turn a screening signal into a reliable diagnosis.
What Echocardiography and Cardiac MRI Can Establish
Echocardiography and cardiac MRI are useful to support suspicion for ATTR-CM, but they aren’t definitive on their own. Findings such as increased wall thickness, restrictive physiology, biatrial enlargement, and abnormal longitudinal mechanics may fit ATTR-CM, yet they overlap with other cardiomyopathies and pressure-loading states. These tests help define the phenotype and should be interpreted alongside laboratory and scintigraphic findings rather than used as standalone proof.
How Monoclonal Testing Changes the Reading of PYP
The pivotal interpretive step is monoclonal testing because it determines what a positive scan means. Serum free light chain testing together with serum and urine immunofixation establishes whether an imaging-led nonbiopsy pathway remains credible or whether AL amyloidosis must stay in the foreground. When monoclonal studies are negative and the phenotype fits, 99mTc-PYP scintigraphy can strongly support ATTR-CM. If results are abnormal or equivocal, tissue confirmation and amyloid typing become more important because the nonbiopsy pathway is less reliable. This is the same logic that governs AL exclusion in the differential diagnosis workup.
Where TTR Genetic Testing Fits
TTR genetic testing is used once the diagnostic foundation is in place. Its value is in distinguishing hereditary from wild-type disease and informing family assessment, not in replacing phenotype, monoclonal evaluation, or scintigraphic evidence. In other words, genotype subtypes a diagnosis established through the broader workup.
Clinical Decision Point
A nonbiopsy diagnosis of ATTR-CM is justified when three findings align: a compatible phenotype, a negative monoclonal screen, and a positive bone-avid scan confirmed by single-photon emission computed tomography (SPECT). When the monoclonal screen is abnormal, the scan is equivocal, or the findings conflict, the decision shifts toward tissue biopsy with amyloid typing or referral, instead of relying on imaging alone.
Frequently Asked Questions
Why is ATTR-CM diagnosis not usually based on one test alone?
Diagnosis depends on how phenotype, monoclonal testing, and confirmatory imaging fit together, not on a single abnormal finding in isolation.
What role do echo and cardiac MRI play in the criteria?
They help define a compatible phenotype and raise suspicion, but their findings aren’t specific enough to establish ATTR-CM on their own.
Why does monoclonal testing change how PYP findings are read?
Abnormal monoclonal studies keep AL amyloidosis in active consideration and reduce the certainty of an imaging-based nonbiopsy ATTR diagnosis, often shifting the workup toward tissue typing.
What does TTR genetic testing add once ATTR-CM is suspected?
It distinguishes hereditary from wild-type disease and informs family assessment, but it doesn’t replace the core diagnostic workup.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. PubMed
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.